Loading
A phase 2 trial of regorafenib in colorectal cancer, run by National Cancer Institute, Naples, now recruiting.
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07213570 by National Cancer Institute, Naples, with a registry enrolment figure of 60 participants, started 2025-10-16 and due to reach its primary completion in 2026-10. Interventions recorded: standard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506). Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression Free Survival rate at 6 months in the two arms.. Colorectal eligibility wording from the registry: "Histologically proven of colorectal adenocarcinoma". Sites: Italy. No results are recorded here; the registry entry is the source.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.